Ali Sheikh Muhammad Ebad, Hafeez Muhammad Hassan, Nisar Omar, Fatima Sarosh, Ghous Humaira, Rehman Mahwish
Dr Ruth KM Pfau Civil Hospital, Karachi, Pakistan.
Shalamar Medical and Dental College (SMDC), Lahore, Pakistan.
Hematol Transfus Cell Ther. 2022 Jan-Mar;44(1):76-84. doi: 10.1016/j.htct.2020.12.006. Epub 2021 Feb 3.
Preoperative anemia is a common finding. Preoperative allogeneic transfusion, iron therapy, vitamin supplementation and erythropoietin therapy are the current management strategies for preoperative anemia. Previous reviews regarding erythropoietin were limited to specialties, provided little evidence regarding the benefits and risks of erythropoietin in managing preoperative anemia and included non-anemic patients. The purpose of our systematic review was to determine the role of erythropoietin solely in preoperatively anemic patients and to investigate the complications of this treatment modality to produce a guideline for preoperative management of anemic patients for all surgical specialties. The PubMed/Medline, Google Scholar, and Cochrane Library were searched for randomized trials evaluating the efficacy of erythropoietin in preoperative anemia. The risk ratio (RR) and standardized mean difference (SMD) was used to pool the estimates of categorical and continuous outcomes, respectively. Allogeneic transfusion and complications and the 90-day mortality were the primary outcomes, while the postoperative change in hemoglobin, bleeding in milliliters and the number of red blood cell (RBC) packs transfused were the secondary outcomes. Results: Eight studies were included, comprising 734 and 716 patients in the erythropoietin group and non-erythropoietin group, respectively. The pooled estimate by RR for allogeneic transfusion was 0.829 (p = 0.049), while complications and the 90-day mortality were among the 1,318 (p = 0.18) patients. Conclusion: Preoperative erythropoietin provides better outcomes, considering the optimization of preoperative anemia for elective surgical procedures. The benefits of erythropoietin are significantly higher, compared to the control group, while the risks remain equivocal in both groups. We recommend preoperative erythropoietin in anemic patients.
术前贫血是一种常见现象。术前异体输血、铁剂治疗、维生素补充和促红细胞生成素治疗是目前针对术前贫血的管理策略。以往关于促红细胞生成素的综述局限于特定专科,关于促红细胞生成素在治疗术前贫血中的益处和风险提供的证据很少,且纳入了非贫血患者。我们进行系统综述的目的是确定促红细胞生成素在术前贫血患者中的单独作用,并调查这种治疗方式的并发症,以便为所有外科专科制定贫血患者术前管理指南。我们在PubMed/Medline、谷歌学术和考克兰图书馆中检索了评估促红细胞生成素治疗术前贫血疗效的随机试验。风险比(RR)和标准化均数差(SMD)分别用于汇总分类和连续结果的估计值。异体输血、并发症和90天死亡率是主要结局,而术后血红蛋白变化、出血量(毫升)和输注红细胞包的数量是次要结局。结果:纳入了8项研究,促红细胞生成素组和非促红细胞生成素组分别有734例和716例患者。RR对异体输血的汇总估计值为0.829(p = 0.049),而1318例患者中存在并发症和90天死亡率(p = 0.18)。结论:考虑到对择期手术术前贫血的优化,术前使用促红细胞生成素可带来更好的结果。与对照组相比,促红细胞生成素的益处显著更高,而两组的风险仍不明确。我们建议对贫血患者术前使用促红细胞生成素。